The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Moureau G, Zarrouk E, Hoton D, Saint-Marcoux F, Boland L, Haufroid V, Hantson P

Flecainide-induced pneumonitis: a case report.

Journal of medical case reports 2022 Nov 02;16;404 — 2022 Nov 02 — 404

Huang HD, Pietrasik GM, Serafini NJ, Sharma PS, Krishnan K, Trohman RG

Drug-induced acute pneumonitis following initiation of flecainide therapy after pulmonary vein isolation ablation in a patient with mitral stenosis and previous chronic amiodarone use.

HeartRhythm case reports 2019 Jan;5;53-55 — 2019 Jan — 53-55

Robain A, Perchet H, Fuhrman C

Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.

Acta cardiologica 2000 Feb;55;45-7 — 2000 Feb — 45-7

Hanston P, Evrard P, Mahieu P, Wallemacq P, Friob M, Hassoun A

Flecainide-associated interstitial pneumonitis.

Lancet (London, England) 1991 Feb 09;337;371-2 — 1991 Feb 09 — 371-2